Chat with this content: Summary, Analysis, News...
Share on Reddit
Amplifon: The Sound of Global Consolidation
How a British WWII Spy Built the World's Dominant Hearing Care Empire from a Basement in Milan
I. Introduction: A Startup Before Startups Existed
The monsoon rains of postwar Europe had barely dried when, in 1950, a most unlikely entrepreneur opened a small laboratory in the heart of Milan. British engineer Charles Holland, a former major in the United Kingdom Army active in the Italian Resistance, had a mission: to help people who had suffered hearing damage due to the bombings of the Second World War.
This origin story has all the elements of a Hollywood pitch: a decorated war hero parachuting behind enemy lines, falling in love with an Italian woman, and then deciding that the devastation around him presented not just tragedy, but opportunity. Holland founded Amplifon in Milan, Italy in 1950, in part because of his experience with servicemen suffering hearing loss in the war, and because of the invention of the transistor in the late 1940s.
Seventy-five years later, what began as a basement startup has become the world's largest hearing aid retailer. Amplifon S.p.A. has reported robust financial results for the full year 2024, with consolidated revenues reaching €2.4 billion. The company acquired approximately 400 new points of sale, primarily in North America, France, Germany, and China, boosting its global presence and surpassing 10,000 points of sale worldwide.
The numbers tell a story of relentless execution. Since 2015, the Amplifon stock value tripled, outperforming the FTSE MIB, the index of the top 40 listed companies in the Borsa Italiana. As of August 2018, the share price had risen nearly 1,000% since its IPO. This is a company that has mastered the art of rolling up fragmented markets, pioneering digital transformation in a decidedly analog industry, and riding demographic tailwinds that will only strengthen in the decades ahead.
This article explores the full Amplifon story—from its improbable founding to its current position as the undisputed global leader in hearing care retail—and examines the strategic decisions, competitive dynamics, and market forces that will shape its future.
II. The Founding Story: A Spy's Post-War Purpose (1944-1950)
Picture the Apennine Mountains of Emilia-Romagna in 1944. Allied bombers thunder overhead while Italian partisans wage a shadow war against Nazi occupation. Among them: a young British major named Algernon Charles Holland, who had parachuted in to coordinate resistance operations.
Algernon Charles Holland MBE MC (10 February 1919 - 2001) was a British businessman and the founder of Amplifon. Holland was born on 10 February 1919 in Horsham, Sussex. His father, Algernon Holland, a Captain in the Royal Air Force, died in the First World War, on 21 September 1918, before he was born.
The Holland family story was one marked by military sacrifice. His mother, Helen Ruth Menzies, was Scottish, born in Argentina, of Quinta Rannock, San Ferriemdo, Buenos Aires, Argentina, and in 1921, they moved to Buenos Aires, and he was educated there at the English College. This cosmopolitan upbringing—raised in South America, educated in England, fighting in Italy—would inform Holland's later global ambitions.
In the Second World War, Holland served with Special Operations Executive. He was also awarded the Bronze Star by the United States Government in 1948. After the war the courageous veteran dedicated his life to providing better hearing for people affected by the conflict and he subsequently launched Amplifon in 1950.
When peace came, Holland didn't return to Britain. In 1950, Holland married Anna Maria Formiggini. The marriage anchored him to Italy, and his wartime experiences had shown him something profound: countless soldiers and civilians had suffered irreversible hearing damage from explosions and artillery bombardment.
The timing was fortuitous from a technological perspective. The transistor—invented at Bell Labs in 1947—was about to revolutionize electronics, including hearing aids. Pre-transistor hearing aids were vacuum-tube devices, bulky and impractical. Holland saw an opportunity to distribute and fit these new miniaturized devices across Italy.
Amplifon was founded in 1950 in Milan by Algernon Charles Holland, a former official of the British special forces, involved in the Italian Resistance movement. At the end of World War II, he started a company aimed at supporting those who experienced hearing loss due to the conflict.
The unique origin—a foreigner founding a healthcare business in postwar Italy—was part necessity, part mission, part market opportunity. Italy's healthcare infrastructure was rebuilding, and there was no established hearing care industry to speak of. Holland essentially invented the category.
What makes this story particularly remarkable is how personal the mission remained. Holland wasn't building an industrial conglomerate; he was solving a problem he had witnessed firsthand. This purpose-driven approach would become embedded in Amplifon's corporate DNA—a genuine commitment to improving lives rather than simply moving product.
III. Building Italy's Hearing Care Leader (1950s-1990)
From that basement laboratory, Holland didn't simply open stores. He invented an entirely new approach to hearing care distribution.
In postwar Italy, infrastructure was devastated and travel was difficult. Many people who needed hearing aids simply couldn't reach urban medical centers. Holland's solution was ingenious: bring the service to them. He equipped pickup trucks as mobile hearing laboratories, traversing the Italian countryside to reach patients in remote villages.
These mobile units served multiple purposes. They provided immediate access to underserved populations. They generated awareness about hearing solutions in communities that had never encountered such technology. And they built trust—the sight of the Amplifon truck arriving became synonymous with hope for families struggling with hearing loss.
As Italy rebuilt and modernized through the 1950s, Amplifon transitioned from mobile units to permanent retail locations. In the 1960s and the 1970s, Amplifon opened stores in every region of Italy, becoming the market leader in the supply, sales, and fitting of hearing aids.
This expansion strategy revealed a critical insight about the hearing care market: distribution matters enormously. Unlike pharmaceuticals that can be shipped or medical procedures performed in centralized hospitals, hearing aids require ongoing fitting, adjustment, and service. The relationship between audiologist and patient is intimate and long-term—often spanning decades as patients return for new devices, adjustments, and care.
Holland understood that building a network of trusted local relationships would create sustainable competitive advantage. He focused on training hearing care professionals, establishing protocols for customer service, and creating a consistent experience across locations.
In 1971, the Amplifon Centre for Research and Studies (CRS) was founded: an independent organisation aimed at spreading knowledge in the audiological and otological fields, through resources and research.
The CRS represented an unusual move for a retail distributor—investing in clinical research and professional education. But Holland recognized that advancing the broader field of audiology would strengthen Amplifon's position. By training the next generation of hearing care professionals and pushing forward the science of audiology, Amplifon positioned itself not merely as a retailer but as an industry leader.
By the early 1990s, Amplifon had established unquestioned dominance in the Italian market. The company had built relationships with ENT physicians, developed proprietary service protocols, and created brand recognition that competitors couldn't match. Italy's hearing aid market essentially belonged to Amplifon.
But Holland and his team saw larger horizons. Italy, after all, represented just one country in a fragmented global market. The same dynamics that had enabled Amplifon's success—the need for local service, the importance of professional relationships, the recurring nature of hearing care—existed everywhere. The company began contemplating international expansion.
IV. Digital Revolution & International Expansion (1990s-2001)
The 1990s brought two transformative developments that would reshape Amplifon's trajectory: the digital revolution in hearing aid technology and the beginning of systematic international expansion.
The Digital Hearing Aid Inflection Point
Until the mid-1990s, hearing aids were essentially analog amplifiers. They took sound waves, made them louder, and delivered them to the ear. The results were imperfect—background noise was as amplified as speech, feedback squealed, and customization was limited.
Digital signal processing changed everything. During the 90s, Amplifon began tailoring the services to the client, rolling out the first digital hearing aids in Italy in 1996.
Digital hearing aids could process sound in real-time, separating speech from noise, adapting to different environments, and being precisely programmed to each patient's unique hearing profile. The fitting process became more sophisticated—and more valuable. Suddenly, the expertise of the audiologist mattered more than ever, as proper programming could mean the difference between a device that transformed a patient's life and one that sat unused in a drawer.
For Amplifon, this technological shift validated its service-centric business model. Companies that competed purely on device price found themselves disadvantaged; the devices were only as good as their fitting and ongoing adjustment. Amplifon's investment in professional training and customer relationships paid dividends.
European Expansion
In 1992, a new company was founded in Spain, Amplifon Iberica, which expanded into Portugal a few years later. Between 1998 and 2000, Amplifon entered Switzerland, Austria, France, Netherlands and the United States markets through acquisitions.
The expansion playbook became clear: identify markets with similar dynamics to Italy (fragmented, service-dependent, aging populations), acquire local players with established networks and relationships, and apply Amplifon's operational expertise to drive growth.
This approach differed markedly from organic expansion. Rather than slowly building stores and recruiting audiologists in unfamiliar markets, Amplifon bought existing businesses that already had infrastructure, customer relationships, and local knowledge. The acquirees gained access to Amplifon's scale, technology investments, and best practices. The synergies were immediate.
The Miracle-Ear Acquisition (1999) – Key Inflection Point #1
The most significant deal of this era—and arguably in Amplifon's entire history to that point—was the 1999 acquisition of Miracle-Ear in the United States.
Miracle-Ear, Inc. is a hearing aid and hearing care company consisting of a network of franchised and corporately owned retail locations. The company is a subsidiary of Amplifon, the worldwide leader in hearing care and hearing aid retail based in Milan, Italy. Miracle-Ear's U.S. headquarters are located in Minneapolis, Minnesota. As of 2023 it has more than 1,500 locations in the United States, and it is the best-known hearing aid brand in the U.S.
The company remained under Dahlberg Inc.'s ownership until 1993, when Dahlberg sold Miracle-Ear to Bausch & Lomb for $139 million. In 1999, Bausch & Lomb divested its hearing aid division, selling Miracle-Ear to Amplifon S.p.A.
The Miracle-Ear acquisition gave Amplifon immediate access to the world's largest hearing aid market. But it also introduced a different business model: the franchise system. While Amplifon's European operations were primarily company-owned stores with employees on payroll, Miracle-Ear operated through independent franchisees who owned their local businesses while using the Miracle-Ear brand and systems.
The franchise model created both opportunities and challenges. Franchisees were motivated owner-operators with deep local knowledge. But Amplifon had less direct control over service quality and customer experience. Over time, Amplifon would develop a hybrid strategy—owning some stores directly while supporting franchisees—that leveraged the advantages of both approaches.
Since the late 1990s, Amplifon has pursued international expansion, a strategy driven by Susan Carol Holland, daughter of Charles Holland, who has served as Vice Chairperson since 1993 and Chairperson since 2011.
The generational transition was underway. Charles Holland had built Amplifon from nothing into Italy's dominant player. His daughter Susan Carol would oversee its transformation into a truly global enterprise.
V. IPO and Global Consolidation (2001-2015)
Going Public
On June 27th, 2001, Amplifon was listed on the Italian Stock Exchange and, in 2008, became part of the STAR segment, for stocks committed to complying with stricter requirements.
The IPO marked Amplifon's transition from a family-controlled private company to a publicly traded enterprise. The timing was challenging—2001 brought the dot-com crash and post-9/11 uncertainty—but Amplifon's stable, recurring revenue business model provided resilience. Hearing loss doesn't follow economic cycles; people need to hear regardless of stock market gyrations.
Public listing provided several strategic benefits. Access to capital markets enabled larger acquisitions. The discipline of quarterly reporting and transparency requirements strengthened corporate governance. And employee stock options aligned management incentives with shareholder value creation.
Acquisition-Driven Growth
With public market access, Amplifon accelerated its acquisition strategy. In 2002, Amplifon acquired the Sonus Corporation in the United States, and later in 2003 took hold of the National Hearing Centers, a company with stores located primarily in large shopping centres. In the following years Amplifon continued its acquisition strategy in the Netherlands, Germany, the United Kingdom, Ireland and Belgium. In 2010, in fact, the company acquired 100% of National Hearing Care (NHC) in Australia, New Zealand and India.
The NHC acquisition was particularly significant, extending Amplifon's reach into the Asia-Pacific region for the first time. Australia's hearing care market, while smaller than Europe or the US, was highly developed with strong reimbursement systems and an aging population. It would prove to be a launchpad for later expansion in the region.
With the acquisition of National Hearing Care (NHC), Amplifon expanded its activities to Australia, New Zealand, and India. Between 2012 and 2014 the company also entered Turkey and Israel.
Each acquisition followed a similar pattern. Amplifon would identify market leaders with strong local brands and professional teams. The purchase price reflected both current earnings and the strategic value of market position. Post-acquisition, Amplifon would integrate backend systems while preserving local brand identities and customer relationships.
The Billion Euro Milestone
Amplifon continued to grow and its revenues exceeded the billion euro threshold in 2015 thanks to a solid strategy, careful planning, and strong execution.
Reaching €1 billion in revenue represented more than a psychological milestone. It confirmed that Amplifon's roll-up strategy was working at scale. The company had successfully navigated cultural differences across countries, integrated dozens of acquisitions, and maintained service quality while growing rapidly.
By 2015, Amplifon had established leadership positions in most major European markets, created a substantial presence in the Americas through Miracle-Ear, and planted flags in Asia-Pacific. The foundation was laid for even more ambitious growth.
VI. The GAES Acquisition: Transformational Deal (2018) – Key Inflection Point #2
If the Miracle-Ear acquisition opened America for Amplifon, the GAES acquisition cemented its global leadership and demonstrated the company's ability to execute transformational deals.
In December 2018, Amplifon made its greatest ever acquisition: GAES, the largest privately-owned specialty hearing care retailer worldwide and undisputed leader in the Spanish market.
The Target
Founded in 1949, GAES is today the largest privately-owned hearing aid specialty retailer worldwide. The company is the clear leader in Spain, 10th largest worldwide hearing aid retail market, still significantly underpenetrated (~15-20%) and with strong growth potential.
GAES and Amplifon were remarkably similar companies. Both were founded in the late 1940s by mission-driven entrepreneurs. Both had built dominant positions in their home markets through service excellence and professional development. Both emphasized brand trust and long-term customer relationships.
The GAES Group, founded in 1949 in Barcelona, is the leader in hearing care solutions in Spain and is also present in Portugal, Andorra and six other Latin American countries (Argentina, Chile, Ecuador, Panama, Colombia and Mexico). GAES, similarly to Amplifon, leverages on both its highly valued and recognized brand and its extensive distribution network, the largest in Spain with around 500 points of sales and other 100 points of sales in other markets.
Deal Structure
Amplifon signed a definitive agreement for the acquisition of GAES group from the GassĂł family and other minority shareholders. The equity value to be paid in cash amounts to Euro 528 million, with a net financial position expected to be around zero.
Amplifon announces today the completion, after the receipt of the unconditional clearance from the Spanish and Portuguese antitrust authorities, of the previously announced acquisition of GAES for a total purchase price of around Euro 530 million.
The deal structure reflected Amplifon's disciplined approach. Paying cash eliminated deal uncertainty and integration complexity. The clean balance sheet (net financial position around zero) meant Amplifon was acquiring a healthy, well-managed business without inherited debt burdens.
Strategic Rationale
Enrico Vita, Chief Executive Officer of Amplifon, commented: "This major acquisition represents a key milestone in the history of our Company and perfectly fits Amplifon's growth strategy, allowing us to consolidate our global leadership and enabling us to become market leader in Spain, as well as consolidate our market position in Portugal while entering also the Latin American region. The combination with GAES' profitable business, the benefits of greater scale and the strong financial profile will enable us to successfully pursue our recently communicated development plans."
The synergy thesis was compelling. The deal is expected to result in run-rate annual synergies at EBITDA level of Euro 20 million by 2021, leveraging best brands, greater scale and best practices sharing.
Beyond immediate synergies, GAES opened Latin America—a region where Amplifon had no presence. The Spanish-speaking markets of Argentina, Chile, Colombia, Ecuador, Mexico, and Panama suddenly became accessible through GAES's established operations.
Integration Success
The GAES integration proceeded faster and more smoothly than planned. By late 2019, Amplifon had completed the complex initial phase, capturing synergies ahead of schedule. The success reflected lessons learned from dozens of prior acquisitions and Amplifon's mature integration playbook.
Index Inclusion
Amplifon is listed on Euronext Milan since 2001 and part of Euronext STAR Milan since 2008. Since December 2018 Amplifon is part of the FTSE MIB index, and since June 2019 it is also part of the Stoxx Europe 600 index as well.
Inclusion in Italy's benchmark index brought increased visibility among institutional investors and triggered automatic buying from index-tracking funds. The Stoxx Europe 600 inclusion extended this visibility to pan-European investors.
VII. Digital Transformation & Amplifon Product Experience (2018-2020)
While executing the GAES acquisition, Amplifon simultaneously launched its most ambitious technology initiative: the Amplifon Product Experience.
In 2018 Amplifon initiated a program of strong technological innovation aimed at customer experience: it launched in Italy the Amplifon Product Experience, made of the Amplifon product line and its multichannel ecosystem.
The Strategic Shift
Historically, hearing aid retailers sold devices manufactured by others—Sonova's Phonak brand, Demant's Oticon, WS Audiology's Signia, and so forth. The retailer's value-add was service: testing, fitting, and ongoing care.
The Amplifon Product Experience represented a strategic evolution. Amplifon began curating hearing aid families under its own brand, selecting the best technology from manufacturing partners and packaging it with Amplifon's service ecosystem. The devices remained manufactured by established suppliers, but the brand, marketing, and customer relationship belonged to Amplifon.
This approach had several advantages. It strengthened Amplifon's brand identity with consumers. It reduced dependence on any single manufacturer. It enabled Amplifon to design complete solutions—device plus app plus service—rather than simply reselling components.
AmplifonX: The In-House Startup
AmplifonX is a new corporate unit acting as a start-up, devoted to Innovation. AmplifonX is the new organizational structure to support the acceleration of the Group's digital innovation strategy. It is a team model that combines business and tech organizations, shortening the go-to-market timeline in a fully agile perspective. A start-up within the Company, able to boost a strong acceleration in the creation of highly-innovative digital products and services.
The team is made by the so-called "X-ers", on average below 30 y.o., coming from different backgrounds - from engineering to self-made development. At the beginning of 2022, AmplifonX was created from the merger of Otohub (start-up acquired in 2019) and the Company's digital team.
AmplifonX represents a fascinating organizational experiment. Rather than assigning innovation to an existing department, Amplifon created a separate unit with startup culture, younger employees, and agile methodologies. The unit operates with significant autonomy while remaining integrated with the broader organization.
Proprietary Tools: OtoPad and Ampli-Care
OtoPad is ANSI and ISO compliant, NOAH compatible, HIPAA compliant tablet-based audiometer. Fully owned by Amplifon, designed in Amplifon, for Amplifon only: OtoPad is a dramatic competitive advantage.
The OtoPad exemplifies Amplifon's approach to technology. By developing proprietary audiometric tools, Amplifon standardizes and optimizes the hearing assessment process across its global network. Competitors using off-the-shelf equipment cannot match the integration and data collection capabilities.
The company continues to improve its customer offering by leveraging three key assets: leading sector brands, deep consumer knowledge, and an innovative customer experience. Through its new Ampli-Care platform, Amplifon aims to deliver a revolutionary and increasingly tailored audiological experience.
The Amplifon App and Ampli-Care platform extend the customer relationship beyond store visits. Patients can adjust their hearing aids remotely, schedule appointments, access support, and receive personalized recommendations. This digital touchpoint creates ongoing engagement and provides Amplifon with valuable data about device usage and customer needs.
VIII. FDA OTC Hearing Aids Rule (2022) – Key Inflection Point #3
In August 2022, the United States Food and Drug Administration upended decades of hearing aid regulation with a single rule change.
Hearing health care in the United States has entered a new era. On August 17, 2022, the U.S. Food and Drug Administration ("FDA") implemented rules allowing for the sale of over-the-counter ("OTC") hearing aids to adults with perceived mild to moderate hearing loss.
The Regulatory Shift
The Food and Drug Administration (FDA) is establishing a regulatory category for over-the-counter (OTC) hearing aids and making related amendments to update the regulatory framework for hearing aids. Specifically, it defines OTC hearing aids and establishes applicable requirements; amends existing rules for consistency with the new OTC category; repeals the conditions for sale applicable to hearing aids; amends the existing labeling requirements for hearing aids.
Consumers may purchase OTC hearing aids without involvement of a hearing care professional or the need to undergo any sort of objective hearing assessment.
For the first time, adults with perceived mild-to-moderate hearing loss could walk into a pharmacy, big-box retailer, or electronics store and purchase a hearing aid without seeing an audiologist or obtaining a prescription. The FDA's stated goal was to improve access and affordability—hearing aids had long been expensive, and many people who could benefit never sought professional care.
The Bull Case: Market Expansion
Optimists argued that OTC hearing aids would expand the overall market. Millions of Americans who had never addressed their hearing loss might now try an affordable OTC device. Some portion of these users would discover their hearing loss was more severe than expected and seek professional care. In this view, OTC devices served as a "gateway" to the professional market, ultimately benefiting companies like Amplifon.
Moreover, the OTC category explicitly targeted mild-to-moderate hearing loss. Patients with more severe conditions—who require sophisticated programming, multiple adjustments, and ongoing audiological care—would still need professional services. Amplifon's core customers weren't going anywhere.
The Bear Case: Disruption Risk
Skeptics warned that OTC represented a fundamental challenge to the traditional hearing care model. Consumer electronics giants like Apple, Samsung, and Bose had the engineering expertise and distribution reach to dominate the OTC category. If consumers learned to self-fit devices using smartphone apps, what was the value of professional audiologists?
As part of the FDA's regulatory changes, non-OTC hearing aids have been reclassified by the FDA from "restricted medical devices" to "prescription medical devices." OTC hearing aids should not be mistaken as a replacement for prescription hearing aids, which are customized and finely tuned by licensed professionals to meet the individual needs of patients.
Amplifon's Response
Amplifon navigated the OTC disruption by doubling down on its service differentiation. The company emphasized that professional hearing care addresses more than amplification—it involves understanding a patient's lifestyle, fitting devices precisely to ear anatomy, programming for specific hearing loss profiles, and providing ongoing support as needs evolve.
Consumers should consider undergoing an objective hearing evaluation prior to using any amplification device to ensure its safety and efficacy.
Three years after the OTC rule took effect, the initial disruption fears have proven overstated. While OTC devices have found a niche, professional hearing care has continued growing. Many OTC purchasers discovered that self-fitting was difficult and outcomes disappointing, leading them to seek professional help. The complexity of hearing loss—unique to each individual—proved resistant to commoditization.
IX. China Expansion & Bay Audio (2018-Present) – Key Inflection Point #4
While navigating OTC disruption in the US, Amplifon aggressively expanded in the Asia-Pacific region, particularly China.
The China Opportunity
China is one of Amplifon's latest additions to its global network and represents a strategic priority for the group in the coming years. Amplifon entered the Chinese market in 2018. In just five years, the company has steadily expanded to become one of the leading players in the country's hearing care sector, boasting a network of over 400 stores spread across 15 regions and employing around 1,000 hearing aid specialists.
In 2018 Amplifon entered the Chinese market through a joint venture and has been growing strongly since then. The hearing care market in China is a major opportunity for medium-long term growth. Its vast size, current low penetration and highly fragmented structure contribute to estimating strong growth in the future. At the end of 2024, the network in the country exceeds 500 points of sale.
The China market thesis was straightforward: a massive population with rapidly improving living standards and an aging demographic profile similar to developed markets, but with hearing aid penetration rates far below Western levels. The addressable market was enormous.
In 2021, Amplifon further expanded its presence in Australia through the acquisition of Bay Audio, and in the following years expanded its presence in China, where it counts on 500 stores at the end of 2024, representing a unique opportunity in the medium-long term given the size of the market and its growth potential.
Bay Audio: Australia Consolidation
Amplifon announces today that it has signed a definitive agreement for the acquisition of Bay Audio Pty Limited ("Bay Audio") from Peter and Anya Hutson, former founders of Bay Audiology in New Zealand, and from other minority shareholders. The cash-out amounts to AUD 550 million (around Euro 340 million), on a cash and debt free basis.
Bay Audio, a leading private independent Australian hearing care retailer, operates a network of over 100 points of sale located in high-traffic premiere shopping malls across the East Coast. In the financial year closed on May 31st 2021, despite the impact of the Covid-19 pandemic, Bay Audio posted revenues of around AUD 100 million (around Euro 63 million) and a Recurring EBITDA of over AUD 30 million.
The Bay Audio acquisition was Amplifon's second-largest ever, after GAES. It consolidated Amplifon's position in Australia, creating a dominant platform through the combination of the legacy Amplifon/NHC business with Bay Audio's complementary network.
Bay Audio, founded in 2007, is controlled by major shareholders Peter and Anya Hutson, former founders of Bay Audiology in New Zealand (part of the Amplifon Group since 2010).
There's a lovely symmetry in this transaction: Bay Audio's founders had previously built and sold Bay Audiology in New Zealand to Amplifon, then started fresh in Australia. When Amplifon acquired Bay Audio, the founders were reunited with their earlier creation—now as part of a global enterprise they had helped build.
X. Current State & US Acceleration (2024-2025)
By 2024, Amplifon had become a fundamentally different company than it was even five years earlier.
In 2024 Amplifon continued along its strong growth path with revenues exceeding 2.4 billion euros thanks to above-market organic performance and an acceleration in M&A, with 400 new points of sale acquired in Europe, the United States and China, despite a European market performance which was below expectations. More in detail, thanks to another year of significant growth, the United States has become our top market in terms of revenue.
US Market Leadership
Amplifon is also accelerating its growth in the US thanks to the acquisition of our franchisees' points of sale. The US network is now made of 400 direct shops and 1,210 points of sale in franchising.
The shift in US strategy is notable. For years, Miracle-Ear operated primarily through franchisees. More recently, Amplifon has been acquiring franchisee businesses and converting them to company-owned operations. This gives Amplifon greater control over the customer experience and more direct access to customer relationships and data.
The transaction perfectly fits Amplifon's strategy aimed at further strengthening its position in the main market in the world: the combination of the acquired business with Miracle-Ear's current direct retail network will enable the Company to further accelerate its development in the US, leveraging on added scale. After this acquisition, Miracle-Ear network reaches around 350 direct retail points of sale, in addition to the over 1,200 franchise locations.
The US becoming Amplifon's largest market by revenue represents a strategic milestone. Decades after acquiring Miracle-Ear, the American business now drives the company's growth and represents its largest opportunity.
Global Footprint
Amplifon's around 19,400 employees and partners worldwide strive every day to understand the unique needs of every customer, delivering exclusive, innovative and highly personalised products and services.
Starting in the 1990s, Amplifon became a global leader in the sector with a 13 percent share of the market. Amplifon currently operates in 26 countries across five continents, with nearly 10,000 retail outlets and a workforce of more than 20,000 people, including over 10,000 hearing aid specialists.
2025 Outlook
Net financial debt was 1,174.7 million euros at September 30th, 2025, with financial leverage at 2.09x. "In the third quarter we recorded a material improvement in revenue trend with respect to the second quarter, with a return to organic growth compared to the prior year."
Amplifon is accelerating the 'Fit4Growth' program with initiatives that will contribute to structural improvements in the Group's performance.
The "Fit4Growth" initiative signals management's focus on operational efficiency alongside growth. After years of rapid expansion, there's recognition that optimizing the existing network can generate meaningful improvements in profitability.
XI. Family Control & Leadership
Amplifon's governance structure represents a fascinating hybrid: family control combined with professional management.
The Holland Family
Susan Carol Holland (born 27 May 1956) is an Italian-British billionaire businesswoman, and the chairman of Amplifon, an Italian hearing aid retailer founded in Milan in 1950 by her father Algernon Charles Holland. Holland earned a bachelor's degree in psychology and sociology from Keele University, followed by a diploma in Logopaedia from the Universita degli Studi di Milano. From 1982, she worked as a speech therapist in Milan. In 1988, she became a director of Amplifon SpA, and in 1993, non-executive vice-chair. She owns 44.9% of Amplifon through her family's holding company.
Susan Carol Holland's background in speech therapy and audiology—rather than finance or general management—reflects the company's healthcare orientation. She understands the clinical and technical dimensions of hearing care at a professional level.
Anna Maria Formiggini has been a director of Amplifon since 1980, chair since 1990, and honorary chair since 2011. Their daughter Susan Carol Holland has been chair of Amplifon since 2011.
The family's continued involvement provides stability and long-term orientation. Unlike companies subject to activist pressure or quarterly performance obsession, Amplifon can pursue multi-year strategies with patient capital.
Professional Management
With a bachelor's degree in Mechanical Engineering, Enrico Vita started his career in 1995 at Indesit Company where he worked for 20 years, taking on roles with increasing responsibility in Italy and abroad, until becoming Chief Operating Officer. In March 2014, he joined Amplifon as Executive Vice President for EMEA and then Chief Operating Officer. In October 2015 he was appointed Chief Executive Officer.
Born in 1969, Enrico Vita graduated in Mechanical Engineering in Ancona. After completing military service, he joined Indesit Company, holding increasingly responsible roles over the years both in Italy and abroad. In 2014, after twenty years of collaboration, Enrico Vita left Indesit to join Amplifon as Executive Vice President for the EMEA region. In 2015, he was appointed CEO and General Manager of Amplifon Group.
Vita's background at Indesit—the appliance manufacturer—brought operational excellence and retail management experience to Amplifon. His decade at the helm has been marked by successful acquisition integration, digital transformation, and consistent financial performance.
Enrico emphasized the importance of combining organic growth with strategic acquisitions. Amplifon has invested over €2 billion in M&A over the past decade, focusing on both small and large acquisitions.
The combination of family ownership providing strategic continuity with professional management driving operational excellence has proven effective. Susan Carol Holland sets direction and represents the founder's legacy; Enrico Vita executes the strategy with the rigor expected of a publicly traded company.
XII. Industry Dynamics & Market Opportunity
Understanding Amplifon's investment thesis requires understanding the hearing care market's structural characteristics.
Demographics: The Ultimate Tailwind
According to the World Health Organization, approximately 1.5 billion people worldwide suffer from some form of hearing loss, and that figure is expected to rise to 2.5 billion by 2050.
The World Health Organization (WHO) reports that the global population aged 60 years and older rose from 1 billion in 2021 to 1.4 billion in 2023. Moreover, the WHO also predicts that approximately 2.5 billion individuals will be living with hearing loss in 2024, with 700 million needing rehabilitative services.
These numbers are staggering. The potential addressable market is growing by hundreds of millions of people through demographic forces alone. Hearing loss is strongly correlated with age, and the global population is aging rapidly across virtually all developed and developing markets.
Penetration Gap
Furthermore, a concerning trend has emerged among younger demographics, as over 1 billion young adults are at risk of developing permanent hearing loss due to unsafe listening practices, such as excessive use of headphones or exposure to loud environments.
Even in developed markets, hearing aid penetration remains surprisingly low. Many people who would benefit from hearing aids never obtain them, due to cost, stigma, or lack of awareness. This represents both a public health challenge and a business opportunity.
Market Size and Structure
The global hearing aids market, valued at US$9.74 billion in 2024, stood at US$10.35 billion in 2025 and is projected to advance at a resilient CAGR of 6.8% from 2025 to 2030, culminating in a forecasted valuation of US$14.42 billion by the end of the period.
Over 25% of the market is made up of specialty players including those with an international presence such as vertically integrated hearing aid manufacturers (Sonova, Demant, GN Store Nord, WS Audiology and Starkey), and the so-called national champions, companies with a presence limited to one or two countries. Over 10% is represented by non-specialty players such as pharmacies, supermarkets and opticians' shops; less than 3% is made up of online retailers, who play a marginal role.
The market remains fragmented, with the largest player (Amplifon) holding roughly 13% global share. This fragmentation creates ongoing consolidation opportunities.
XIII. Porter's 5 Forces Analysis
Threat of New Entrants: MODERATE-LOW
Building a hearing care retail network requires significant capital investment, regulatory compliance, and years of relationship-building with audiologists and ENT physicians. The installed base of stores—Amplifon's 10,000+ locations—represents a nearly insurmountable barrier for traditional entrants.
However, the OTC regulatory change has lowered barriers for consumer electronics companies targeting mild hearing loss. Traditional hearing aids, including behind-the-ear (BTE), in-the-ear (ITE), and invisible-in-canal (IIC) devices, face competition from over-the-counter (OTC) hearing aids, which have gained traction due to recent regulatory changes.
The critical question is whether OTC represents a different market (mild hearing loss addressed through consumer electronics) or a substitute threatening Amplifon's core business (moderate-to-severe hearing loss requiring professional care). So far, evidence suggests the former.
Bargaining Power of Suppliers: MODERATE
Amplifon is the world's largest hearing aid retailer. It was founded in 1950 in Milan and now has a presence in over 29 countries. Amplifon does not manufacture its own hearing aids but sells its own branded version of other manufacturers' devices.
Amplifon acts as a global hearing care specialist and retailer. Its top manufacturer brands are Oticon (Demant), Phonak (Sonova), and Sivantos (WS Audiology), and sells all of the Big Five, which also include GN and Starkey.
Amplifon's scale provides bargaining power—as the world's largest retailer, it represents a critical distribution channel for manufacturers. The multi-supplier strategy further reduces dependence on any single manufacturer.
Bargaining Power of Buyers: MODERATE
Hearing care purchasing is highly emotional and tied to quality of life. Patients generally don't comparison shop for hearing aids the way they might for consumer electronics. Professional recommendations carry significant weight.
Government reimbursement programs in many markets create third-party payer dynamics that reduce individual price sensitivity. However, OTC alternatives have increased buyer options for mild cases.
Threat of Substitutes: INCREASING
Beyond OTC hearing aids, emerging technologies pose substitution risks. Cochlear implants serve patients with severe hearing loss. Personal sound amplification products (PSAPs) address some use cases. Consumer earbuds increasingly incorporate hearing enhancement features.
However, none of these substitutes adequately address the needs of patients with moderate-to-severe hearing loss who require professional fitting and ongoing care.
Competitive Rivalry: HIGH
Amplifon has increasingly come into competition with major hearing aid manufacturers, including Sonova, which announced the purchase of AudioNova—Europe's second largest dispensing network after Amplifon—in September 2016. That purchase significantly expanded Sonova's business in the European market by 1,300 stores in 8 countries.
The competitive landscape has intensified as manufacturers have vertically integrated into retail. Sonova (through AudioNova and other acquisitions) and Demant (through HearingLife and Audika) now operate large retail networks alongside their manufacturing businesses. This creates a different competitive dynamic than the fragmented independent market Amplifon traditionally served.
XIV. Hamilton's 7 Powers Analysis
Scale Economies: STRONG
Amplifon's 10,000+ point-of-sale network creates meaningful scale advantages in purchasing (buying power with manufacturers), marketing (brand awareness campaigns amortized across large base), technology (digital platforms developed once, deployed globally), and training (professional education programs efficiently delivered at scale).
Network Effects: MODERATE
Direct network effects are limited—one patient's hearing aid doesn't improve another patient's experience. However, indirect network effects exist through the audiologist talent network (top professionals want to work for the industry leader) and data accumulation (more patients generate more fitting data, improving algorithms and protocols).
Counter-Positioning: STRONG (Historically)
For decades, hearing aid manufacturers hesitated to compete directly with their retail customers. Amplifon's pure retail/service focus allowed it to source from all manufacturers while manufacturers worried about channel conflict. Sonova's AudioNova acquisition in 2016 signaled that this dynamic was changing—manufacturers became willing to compete in retail. However, Amplifon's head start and scale create barriers even as competitors pursue vertical integration.
Switching Costs: HIGH
Hearing aid customers typically have multi-year relationships with their audiologist. Device lifecycles span 5-7 years, during which patients return for adjustments, repairs, and support. Audiologist relationships create emotional switching costs beyond mere data lock-in.
Proprietary platforms like Ampli-care and the Amplifon App drive recurring engagement and create additional stickiness. Patients whose audiometric data and fitting history reside in Amplifon's systems face friction in switching providers.
Branding: STRONG
Amplifon operates a multi-brand strategy: Amplifon in Europe and Asia, GAES in Spain and Latin America, Miracle-Ear in the United States. Each brand carries decades of local recognition and trust. In healthcare decisions, brand trust significantly influences provider selection.
Cornered Resource: MODERATE
Amplifon's workforce boasts over 100 different nationalities, with women representing 74 percent of employees and holding nearly half of all managerial positions.
The company also continued its commitment to corporate responsibility, delivering 575,000 hours of training to employees.
The 10,000+ audiologists and hearing care professionals in Amplifon's network represent a cornered resource. Training and retaining this workforce requires significant ongoing investment. The family control structure provides governance stability that attracts professionals seeking long-term careers rather than frequent ownership changes.
Process Power: STRONG
After decades of acquisitions, Amplifon has developed sophisticated integration playbooks. The company can acquire businesses, integrate backend systems, retain key staff, and extract synergies with predictable effectiveness. This repeatable process enables ongoing roll-up strategy execution.
XV. Bull Case, Bear Case, and Key Metrics
Bull Case
Demographic tailwinds are irresistible. The global population over 65 is doubling by 2050. Hearing loss is strongly correlated with age. This creates structural demand growth for decades regardless of economic cycles or competitive dynamics.
Fragmentation creates ongoing M&A opportunity. With only ~13% global share, Amplifon has room to continue consolidating the market through acquisitions. Each deal adds scale advantages that make subsequent acquisitions more accretive.
OTC expands the market rather than cannibalizing it. Early evidence suggests OTC devices serve a different customer segment (mild hearing loss, self-fit) rather than substituting for professional care (moderate-to-severe, complex fitting). OTC may actually increase awareness and drive referrals to professional services.
Digital transformation creates competitive moats. AmplifonX, OtoPad, Ampli-Care, and the Amplifon App represent proprietary technology investments that competitors cannot easily replicate. Data advantages compound over time.
Management has a proven track record. The Vita/Holland leadership team has delivered consistent results through economic cycles, integrated transformational acquisitions, and navigated regulatory disruption.
Bear Case
Vertical integration by manufacturers intensifies competition. Sonova, Demant, and WS Audiology are investing heavily in retail. As manufacturers control more distribution, Amplifon's leverage as an independent retailer may diminish.
OTC disruption could accelerate. If consumer electronics companies (Apple, Samsung) successfully develop self-fitting hearing solutions using smartphone sensors and AI, the professional fitting model could be disrupted for larger portions of the market.
European market weakness may persist. 2024 results showed softer-than-expected European performance. If this reflects structural challenges rather than cyclical factors, Amplifon's largest regional market may underperform.
Valuation reflects optimistic expectations. At current levels, the stock trades at premium multiples that embed significant growth assumptions. Any disappointment could drive multiple compression.
Leverage has increased. Net financial debt was 1,174.7 million euros at September 30th, 2025, with financial leverage at 2.09x. While manageable, higher leverage reduces flexibility and increases sensitivity to interest rates.
Key Performance Indicators to Monitor
For investors tracking Amplifon's ongoing performance, three metrics merit particular attention:
-
Organic revenue growth rate — This measures underlying business momentum independent of acquisitions and currency effects. Management consistently targets above-market organic growth; tracking actual performance against targets reveals execution effectiveness.
-
Same-store sales growth (like-for-like) — The health of existing stores indicates customer retention, competitive positioning, and pricing power. Declining same-store growth would signal competitive pressure or market saturation.
-
EBITDA margin trajectory — As Amplifon pursues the "Fit4Growth" initiative, margin improvement (or deterioration) signals whether scale advantages are being realized and whether investments in technology and network expansion are translating to profitability.
XVI. Conclusion: The Sound of the Future
Seventy-five years after Charles Holland opened that basement laboratory in Milan, Amplifon stands as a remarkable corporate story: a family-controlled company that achieved global scale without losing its mission-driven culture, a roll-up strategy executed with unusual consistency, a digital transformation undertaken while the core business continued growing.
The company's success rests on a simple but powerful insight: hearing care is fundamentally about service, not products. Devices come and go, technologies evolve, but the relationship between audiologist and patient—understanding individual needs, providing personalized solutions, supporting people through the journey of hearing loss—remains central.
This insight has proven remarkably durable through technological disruption, regulatory change, and competitive pressure. Whether the threat came from digital hearing aids in the 1990s, manufacturer vertical integration in the 2010s, or OTC regulations in the 2020s, Amplifon's response remained consistent: invest in professional excellence, deepen customer relationships, and leverage scale to provide superior service.
The next chapter will test these principles anew. China represents an enormous opportunity but also execution complexity. The US market is becoming more competitive as manufacturers expand retail presence. Technology—AI, telehealth, consumer device integration—will continue disrupting traditional care models.
Yet Amplifon enters this future from a position of strength: market leadership, proven management, family-controlled stability, and 10,000+ points of service touching hundreds of thousands of customers each year. Charles Holland's mission—helping people hear better—remains as relevant as ever in a world where 1.5 billion people experience hearing loss.
For long-term investors, Amplifon offers exposure to powerful demographic tailwinds through a company with defensible competitive advantages and disciplined capital allocation. The business model has proven resilient, the management team has delivered, and the market opportunity stretches decades ahead.
The sound of global consolidation continues—and Amplifon intends to orchestrate it.
Spotify
Apple Podcasts
Amazon Music
Audible
YouTube
Castbox
Pocket Casts